Abstract
L-dopa is the most effective drug in the symptomatic management of PD and extends the life span of PD patients.The question whether L-dopa is neurotoxic remains however unresolved. In recent years, increased Homocysteine (Hcy) levels have been observed in L-dopa treated Parkinsons disease (PD) patients, resulting from L-dopa O-methylation by the enzyme catechol-O-methyltransferase. This review summarizes current evidences supporting the possible role of Hcy as mediator of L-dopa toxicity mainly on dopaminergic neurons.
Keywords: Homocysteine, Levodopa, Parkinson's disease, toxicity, dopaminergic neurons
Letters in Drug Design & Discovery
Title: L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Volume: 2 Issue: 7
Author(s): Stefano Zoccolella, Giovanni Iliceto, Michele deMari, Giovanni Defazio, Paolo Livrea and Paolo Lamberti
Affiliation:
Keywords: Homocysteine, Levodopa, Parkinson's disease, toxicity, dopaminergic neurons
Abstract: L-dopa is the most effective drug in the symptomatic management of PD and extends the life span of PD patients.The question whether L-dopa is neurotoxic remains however unresolved. In recent years, increased Homocysteine (Hcy) levels have been observed in L-dopa treated Parkinsons disease (PD) patients, resulting from L-dopa O-methylation by the enzyme catechol-O-methyltransferase. This review summarizes current evidences supporting the possible role of Hcy as mediator of L-dopa toxicity mainly on dopaminergic neurons.
Export Options
About this article
Cite this article as:
Zoccolella Stefano, Iliceto Giovanni, deMari Michele, Defazio Giovanni, Livrea Paolo and Lamberti Paolo, L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?, Letters in Drug Design & Discovery 2005; 2 (7) . https://dx.doi.org/10.2174/157018005774479113
DOI https://dx.doi.org/10.2174/157018005774479113 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets Targeting Mitochondria for Cardiac Protection
Current Drug Targets Ionic Liquids, Microextraction Methods and Capillary Electrophoresis in Biomedical Research
Current Pharmaceutical Analysis Advancement in Microsponge Drug Delivery System: Preparation Methods, Patents and Commercial Utility
Recent Patents on Drug Delivery & Formulation Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology The Role of Diet in Patients with Metabolic Syndrome
Current Medicinal Chemistry Protective Effects of Pomegranate in Endothelial Dysfunction
Current Pharmaceutical Design microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry Ca2+-Dependent Signaling Pathways in the Heart: Potential Drug Targets for Cardiac Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Life-Threatening Respiratory Syncytial Virus Disease in Children
Current Respiratory Medicine Reviews Editorial [Hot topic: Developing New Anti-Cancer Drugs (Guest Editor: Ricardo De Souza Pereira)]
Recent Patents on Anti-Cancer Drug Discovery Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Periodontal Disease and Periodontal Tissue Regeneration
Current Stem Cell Research & Therapy Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology